(Q95721134)
Statements
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms (English)
E A Sausville
S G Arbuck
R Messmann
D Headlee
K S Bauer
R M Lush
A Murgo
W D Figg
T Lahusen
S Jaken
X Jing
M Roberge
E Fuse
T Kuwabara
1 reference